With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise.
The biotechnology sector, as measured by the XBI ETF, is trading higher today driven by a series of positive company-specific news announcements. Notably, Krystal Biotech (KRYS) released encouraging clinical data for its Gorlin Syndrome treatment, showing significant lesion regression. Additionally, Legend Biotech (LEGN) received FDA clearance for its Investigational New Drug (IND) application for a new CAR-T therapy. This positive news flow contributes to a broader sentiment of a recovering sector, further supported by ongoing M&A activity.